To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
- Investigator
- Torge Rempe
- Status
- Accepting Candidates
- Ages
- 18 Years - 55 Years
- Sexes
- All
Research at a glance
Top areas of exploration
- Aquaporin 4 , 3 publications
- Neuromyelitis Optica , 3 publications
- Autoantibodies , 3 publications
- Disease Progression , 2 publications
Research activity
Active clinical trials
The main objective of the study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period
- Investigator
- Torge Rempe
- Status
- Accepting Candidates
- Ages
- 12 Years - N/A
- Sexes
- All
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical…
- Investigator
- Torge Rempe
- Status
- Accepting Candidates
- Ages
- 18 Years - 55 Years
- Sexes
- All
My publications
Filter publications
23 publications
2022
Longitudinal evaluation of neurologic-post acute sequelae SARS-CoV-2 infection symptoms.
Annals of clinical and translational neurology
PubMed • Publisher's site2022
Therapeutic Advances in Multiple Sclerosis.
Frontiers in neurology
PubMed • Publisher's site2021
Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Multiple sclerosis and related disorders
PubMed • Publisher's site2021
CNS Lymphocytic Vasculitis in a Young Woman With COVID-19 Infection
Neurology Neuroimmunology & Neuroinflammation
Publisher's site2021
Quantification of smooth pursuit dysfunction in multiple sclerosis
Multiple Sclerosis and Related Disorders
Publisher's site